Aeterna Zentaris, Inc. (AEZS) rated Buy
Rodman & Renshaw rated Buy Aeterna Zentaris, Inc. (NASDAQ: AEZS) on 10/03/2007, when the stock price was $13.74.
Since then, Aeterna Zentaris, Inc. has lost 98.69% as of 08/04/2015's recent price of $0.18. If you would have followed this Rodman & Renshaw's recommendation on AEZS, you would have lost 98.68% of your investment in 2862 days.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology. The product pipeline of the Company encompasses compounds at all stages of development, from drug discovery through marketed products. The Company’s principal product candidates include cetrorelix for benign prostatic hyperplasia (BPH) and AEZS-108 for endometrial and ovarian cancers. In January 2007, the Company completed the spin-off of Atrium Biotechnologies Inc., known as Atrium Innovations (Atrium). On November 30, 2007, the Company completed the sale of its Utah-based subsidiary, Echelon Biosciences Inc. (Echelon), to Frontier Scientific Inc.
Rodman & Renshaw
is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.